Statin‐associated muscle symptoms—A review: Individualizing the approach to optimize care
Abstract
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, also known as "statins" are considered first-line pharmacologic therapy for reducing low-density lipoprotein cholesterol (LDL-C). They have been demonstrated efficacy in a variety of patients populations to reduce atherosclerotic cardiovascular disease (ASCVD) risk. Like any pharmacologic therapy, however, they are not without possible adverse effects that can lead to discontinuation, thus leading to a loss of benefit. The most common side effect related to statin therapy impacting compliance is musculoskeletal related, commonly referred to as statin-associated muscle systems (SAMS). While the overall incidence is relatively low, the consequences of nonadherence to statin therapy can have a negative impact on patient care. Therefore, it is important for healthcare providers to understand risk factors, how to diagnose, and how to manage this unfortunate adverse effect in order to optimize care.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Statin intolerance has no consensus definition.
“Given that statin intolerance has no consensus definition [8]”
From Intolerance upon statin rechallenge: A systematic review and meta-analysis of randomized controlled trials (2023) · cites this paper as [8]
Cites
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487 · see citing works
Medication Adherence: Its Importance in Cardiovascular Outcomes
Ho, P. M., Bryson, C. L., & Rumsfeld, J. S. (2009) · Circulation · doi:10.1161/circulationaha.108.768986 · Cited by 1,488 · see citing works
Effect of statins on skeletal muscle function
Parker, B. A., Capizzi, J. A., Grimaldi, A. S., Clarkson, P. M., Cole, S. M., Keadle, J., Chipkin, S., Pescatello, L. S., Simpson, K., White, C. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.136101 · Cited by 500 · see citing works
An assessment by the statin muscle safety task force: 2014 update
Rosenson, R. S., Baker, S. K., Jacobson, T. A., Kopecky, S. L., & Parker, B. A. (2014) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2014.03.004 · Cited by 485 · see citing works
Moriarty, P. M., Thompson, P. D., Cannon, C. P., Guyton, J. R., Bergeron, J., Zieve, F. J., Bruckert, E., Jacobson, T. A., Kopecky, S. L., Baccara-Dinet, M. T., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.08.006 · Cited by 470 · see citing works
N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects
Wood, F. A., Howard, J. P., Finegold, J. A., Nowbar, A. N., Thompson, D. M., Arnold, A. D., Rajkumar, C. A., Connolly, S., Cegla, J., Stride, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031173 · Cited by 274 · see citing works
Handelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., Davidson, M. H., Einhorn, D., Fazio, S., Fonseca, V. A., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2020-0490 · Cited by 248 · see citing works
Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment
Howard, J. P., Wood, F. A., Finegold, J. A., Nowbar, A. N., Thompson, D. M., Arnold, A. D., Rajkumar, C. A., Connolly, S., Cegla, J., Stride, C., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.07.022 · Cited by 198 · see citing works
Banach, M., Rizzo, M., Toth, P. P., Farnier, M., Davidson, M. H., Al-Rasadi, K., Aronow, W. S., Athyros, V., Djuric, D. M., Ezhov, M. V., et al. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1039980 · Cited by 162 · see citing works
Muntean, D. M., Thompson, P. D., Catapano, A. L., Stasiolek, M., Fabis, J., Muntner, P., Serban, M.-C., & Banach, M. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.001 · Cited by 82 · see citing works
Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy
Keating, A. J., Campbell, K. B., & Guyton, J. R. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r509 · Cited by 74 · see citing works
Moon, J., Cohen Sedgh, R., & Jackevicius, C. A. (2021) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.007480 · Cited by 33 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Kraut, R., Wierenga, F., Molstad, E., Korownyk, C., Perry, D., Dennett, L., & Garrison, S. (2023) · PLOS ONE · doi:10.1371/journal.pone.0295857 · Cited by 7 · see citing works
Hamayal, M., Shahid, W., Akhtar, C. H., Shekiba, F., Iftikhar, I., Tahir, M. D., Awwab, M., Hussain, S., Naeem, S., & Hafeez, M. (2024) · Future Cardiology · doi:10.1080/14796678.2024.2388478 · Cited by 6 · see citing works
- Authors
- Wiggins, B. S., Backes, J. M., & Hilleman, D.
- Affiliations
- Medical University of South Carolina (US)
- University of Kansas (US)
- Creighton University (US)
- Corresponding author
- Wiggins, Barbara S.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2022-04-15
- Volume
- 42
- Issue
- 5
- Pages
- 428-438
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W4223944388
- Cited by
- 17
- References
- 12
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 5 · 2023: 6 · 2022: 2
- FWCI
- 0.95
- Type
- journal article
- Language
- en
- Update notices
- correction (2022-06-11)
- Open access
- closed
- Locations
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statin-associated muscle symptoms, statins, statin adverse effects, myalgia, statin intolerance, medication non-adherence, risk factors, diagnosis, LDL cholesterol lowering, atherosclerotic cardiovascular disease
- MeSH terms
- Humans, Cholesterol, LDL, Muscles, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
